US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Aptevo Therapeutics

2.68

-0.0800-2.90%

Post-market: 2.690.0053+0.20%19:45 EDT

Volume:55.29K

Turnover:148.64K

Market Cap:4.83M

PE:-0.09

High:2.85

Open:2.84

Low:2.58

Close:2.76

52wk High:48.78

52wk Low:2.58

Shares:1.80M

Float Shares:1.64M

Volume Ratio:0.81

T/O Rate:3.36%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-29.4999

EPS(LYR):-82.2951

ROE:-420.34%

ROA:-111.49%

PB:0.80

PE(LYR):-0.03

Loading ...

Overview Company News Filings

Aptevo Therapeutics Posts Investor Presentation on Multispecific Immunotherapies for Cancer, Led by Mipletamig in AML

Aptevo Therapeutics files Form 3 initial beneficial ownership statement for Niowave Inc

Aptevo Therapeutics files Form 3 for SVP, CSO Mary Jo Janatpour

Aptevo Therapeutics names Mary Janatpour senior vice president, chief scientific officer

Aptevo, Niowave form 50/50 radiopharmaceutical oncology collaboration

Aptevo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Aptevo net loss widens to $6.7 million in Q1 FY26; operating cash outflow rises to $8 million

Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M

Aptevo says RAINIER trial on track for 2026 completion, Phase 2 dose selection

Aptevo Therapeutics Inc expected to post a loss of $5.60 a share - Earnings Preview

Aptevo says mipletamig combo shows 81% remission in frontline AML trial cohort 5

Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)

Aptevo Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate

Benzinga Earnings

Aptevo Therapeutics reports FY25 EPS ($87.27) vs. ($31,460.23) last year

Aptevo Therapeutics sees cash runway into 4Q26

Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million

Aptevo highlights mipletamig AML data showing 79% remission rate

Aptevo Therapeutics to present at Roth Conference and BIO-Europe Spring

Aptevo reports 86% clinical benefit rate and 0% CRS for mipletamig plus venetoclax and azacitidine in frontline AML trial data

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/APVO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APVO\",,,,,undefined,":{"symbol":"APVO","market":"US","secType":"STK","nameCN":"Aptevo Therapeutics","latestPrice":2.68,"timestamp":1787342400000,"preClose":2.76,"halted":0,"volume":55291,"hourTrading":{"tag":"盘后","latestPrice":2.6853,"preClose":2.68,"latestTime":"19:45 EDT","volume":1935,"amount":5247.8442,"timestamp":1787355912264,"change":0.0053,"changeRate":0.001978,"amplitude":0.121269},"delay":0,"changeRate":-0.02898550724637668,"floatShares":1643541,"shares":1802000,"eps":-29.499943,"marketStatus":"Market Closed","change":-0.08,"latestTime":"08-21 16:00:00 EDT","open":2.84,"high":2.85,"low":2.5801,"amount":148635.4170199,"amplitude":0.09779,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-29.499943,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.76,"preHourTrading":{"tag":"盘前","latestPrice":2.76,"preClose":2.76,"latestTime":"09:17 EDT","volume":740,"amount":2119.05993,"timestamp":1787318257146,"change":0,"changeRate":0,"amplitude":0.054348},"postHourTrading":{"tag":"盘后","latestPrice":2.6853,"preClose":2.68,"latestTime":"19:45 EDT","volume":1935,"amount":5247.8442,"timestamp":1787355912264,"change":0.0053,"changeRate":0.001978,"amplitude":0.121269},"volumeRatio":0.8146236244193196},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APVO\",,,,,undefined,":{"symbol":"APVO","floatShares":1643541,"roa":"-111.49%","roe":"-420.34%","lyrEps":-82.295149,"volumeRatio":0.8146236244193196,"shares":1802000,"dividePrice":0,"high":2.85,"amplitude":0.09779,"preClose":2.76,"low":2.5801,"week52Low":2.5801,"pbRate":"0.80","week52High":48.78,"institutionHeld":0,"latestPrice":2.68,"eps":-29.499943,"divideRate":0,"volume":55291,"delay":0,"ttmEps":-29.499943,"open":2.84,"prevYearClose":9.43,"prevWeekClose":2.94,"prevMonthClose":4.11,"prevQuarterClose":4.44,"fiveDayClose":2.94,"twentyDayClose":4.39,"sixtyDayClose":4.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APVO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-14","symbol":"APVO","fiscalQuarterEnding":"2026/06","expectedEps":-6.02,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786680000000,"reportTimeType":"pre","actualEps":-5.31},{"market":"US","date":"2026-05-13","symbol":"APVO","fiscalQuarterEnding":"2026/03","expectedEps":-5.6,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"post","actualEps":-6.41},{"date":"2026-03-26","symbol":"APVO","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774512000000,"name":null,"time":"Pre-MKt","dateTimestamp":1774497600000,"actualEps":null},{"market":"US","date":"2025-12-30","symbol":"APVO","defaultRemindTime":1767105000000,"type":"split","dateTimestamp":1767070800000,"forFactor":18,"toFactor":1,"ratio":18},{"market":"US","date":"2025-11-06","symbol":"APVO","fiscalQuarterEnding":"2025/09","expectedEps":-2.09,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-2.23}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1758081600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/APVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"APVO","date":"2026-08-21","current":-0.090848,"percent":0.651965,"low":-3.218045,"twenty":-0.680622,"median":-0.19707,"eighty":0.135089,"high":3.317157,"avg":-0.066942,"sd":1.093912,"marketCap":3439249},"quantilePoints":[{"date":"2021-08-27","current":-2.963501,"twenty":-1.209157,"median":-0.729291,"eighty":-0.342703,"marketCap":86036361},{"date":"2021-09-03","current":-3.059587,"twenty":-1.225828,"median":-0.729291,"eighty":-0.342703,"marketCap":88825936},{"date":"2021-09-10","current":-2.887643,"twenty":-1.246922,"median":-0.729291,"eighty":-0.342703,"marketCap":83834065},{"date":"2021-09-17","current":-2.909558,"twenty":-1.295574,"median":-0.729291,"eighty":-0.342703,"marketCap":84470284},{"date":"2021-09-24","current":-2.823586,"twenty":-1.309523,"median":-0.729291,"eighty":-0.342703,"marketCap":81974349},{"date":"2021-10-01","current":-2.639842,"twenty":-1.31973,"median":-0.729291,"eighty":-0.342703,"marketCap":76639899},{"date":"2021-10-08","current":-2.444298,"twenty":-1.342525,"median":-0.729291,"eighty":-0.342703,"marketCap":70962869},{"date":"2021-10-15","current":-2.526899,"twenty":-1.370424,"median":-0.729291,"eighty":-0.342703,"marketCap":73360925},{"date":"2021-10-22","current":-2.402155,"twenty":-1.429717,"median":-0.729291,"eighty":-0.342703,"marketCap":69739371},{"date":"2021-10-29","current":-2.569042,"twenty":-1.507874,"median":-0.729291,"eighty":-0.342703,"marketCap":74584422},{"date":"2021-11-05","current":-2.793243,"twenty":-2.429127,"median":-0.729291,"eighty":-0.342703,"marketCap":81093430},{"date":"2021-11-12","current":-1.949966,"twenty":-2.43823,"median":-0.729291,"eighty":-0.342703,"marketCap":57013115},{"date":"2021-11-19","current":-1.222917,"twenty":-2.43823,"median":-0.729291,"eighty":-0.342703,"marketCap":35755648},{"date":"2021-11-26","current":-2.189524,"twenty":-2.441939,"median":-0.729291,"eighty":-0.342703,"marketCap":64017304},{"date":"2021-12-03","current":-1.177686,"twenty":-2.441939,"median":-0.729291,"eighty":-0.342703,"marketCap":34433179},{"date":"2021-12-10","current":-1.301653,"twenty":-2.441939,"median":-0.729291,"eighty":-0.342703,"marketCap":38057724},{"date":"2021-12-17","current":-1.360286,"twenty":-2.441939,"median":-0.729433,"eighty":-0.342703,"marketCap":39772036},{"date":"2021-12-23","current":-1.318405,"twenty":-2.441939,"median":-0.729433,"eighty":-0.342703,"marketCap":38547527},{"date":"2021-12-31","current":-1.318405,"twenty":-2.441939,"median":-0.729433,"eighty":-0.342703,"marketCap":38547527},{"date":"2022-01-07","current":-1.237994,"twenty":-2.441264,"median":-0.729433,"eighty":-0.343184,"marketCap":36196471},{"date":"2022-01-14","current":-1.209565,"twenty":-2.441264,"median":-0.729433,"eighty":-0.343184,"marketCap":35365274},{"date":"2022-01-21","current":-0.98671,"twenty":-2.441264,"median":-0.729433,"eighty":-0.343184,"marketCap":28849420},{"date":"2022-01-28","current":-0.909649,"twenty":-2.44059,"median":-0.729433,"eighty":-0.343666,"marketCap":26596324},{"date":"2022-02-04","current":-0.934778,"twenty":-2.44059,"median":-0.729433,"eighty":-0.343666,"marketCap":27331029},{"date":"2022-02-11","current":-0.985035,"twenty":-2.439915,"median":-0.729433,"eighty":-0.344147,"marketCap":28800439},{"date":"2022-02-18","current":-0.967608,"twenty":-2.439915,"median":-0.729433,"eighty":-0.344147,"marketCap":28290911},{"date":"2022-02-25","current":-0.974458,"twenty":-2.439915,"median":-0.729433,"eighty":-0.344147,"marketCap":28491201},{"date":"2022-03-04","current":-0.907667,"twenty":-2.439915,"median":-0.729433,"eighty":-0.344147,"marketCap":26538377},{"date":"2022-03-11","current":-0.813475,"twenty":-2.439915,"median":-0.730884,"eighty":-0.344147,"marketCap":23784394},{"date":"2022-03-18","current":-0.869991,"twenty":-2.439915,"median":-0.731099,"eighty":-0.344147,"marketCap":25436784},{"date":"2022-03-25","current":-1.068066,"twenty":-2.439915,"median":-0.731664,"eighty":-0.344147,"marketCap":30393952},{"date":"2022-04-01","current":-1.108536,"twenty":-2.439915,"median":-0.732068,"eighty":-0.344147,"marketCap":31545618},{"date":"2022-04-08","current":-0.948414,"twenty":-2.439915,"median":-0.733014,"eighty":-0.344147,"marketCap":26989028},{"date":"2022-04-14","current":-0.837561,"twenty":-2.439915,"median":-0.735904,"eighty":-0.344147,"marketCap":23834467},{"date":"2022-04-22","current":-0.823484,"twenty":-2.439915,"median":-0.738671,"eighty":-0.344147,"marketCap":23433887},{"date":"2022-04-29","current":-0.749582,"twenty":-2.439915,"median":-0.739917,"eighty":-0.344147,"marketCap":21330846},{"date":"2022-05-06","current":-0.710871,"twenty":-2.439915,"median":-0.740753,"eighty":-0.344147,"marketCap":20229253},{"date":"2022-05-13","current":-0.797056,"twenty":-2.439915,"median":-0.741669,"eighty":-0.344147,"marketCap":23033313},{"date":"2022-05-20","current":-0.788392,"twenty":-2.439915,"median":-0.744513,"eighty":-0.344147,"marketCap":22782951},{"date":"2022-05-27","current":-0.845572,"twenty":-2.439915,"median":-0.74549,"eighty":-0.344147,"marketCap":24435340},{"date":"2022-06-03","current":-0.864632,"twenty":-2.439915,"median":-0.745907,"eighty":-0.344147,"marketCap":24986137},{"date":"2022-06-10","current":-0.689626,"twenty":-2.439915,"median":-0.748131,"eighty":-0.344147,"marketCap":19928823},{"date":"2022-06-17","current":-0.60299,"twenty":-2.439915,"median":-0.747837,"eighty":-0.344147,"marketCap":17425202},{"date":"2022-06-24","current":-0.672299,"twenty":-2.44059,"median":-0.745751,"eighty":-0.343666,"marketCap":19428098},{"date":"2022-07-01","current":-0.620317,"twenty":-2.44059,"median":-0.745306,"eighty":-0.343666,"marketCap":17925926},{"date":"2022-07-08","current":-0.722548,"twenty":-2.44059,"median":-0.745306,"eighty":-0.343666,"marketCap":20880199},{"date":"2022-07-15","current":-0.67923,"twenty":-2.44059,"median":-0.745306,"eighty":-0.343666,"marketCap":19628388},{"date":"2022-07-22","current":-0.696557,"twenty":-2.44059,"median":-0.745673,"eighty":-0.343666,"marketCap":20129112},{"date":"2022-07-29","current":-0.682695,"twenty":-2.44059,"median":-0.745673,"eighty":-0.343666,"marketCap":19728533},{"date":"2022-08-05","current":-0.743341,"twenty":-2.44059,"median":-0.745673,"eighty":-0.343666,"marketCap":21481068},{"date":"2022-08-12","current":3.1943,"twenty":-2.44059,"median":-0.746063,"eighty":-0.336476,"marketCap":22500646},{"date":"2022-08-19","current":2.478834,"twenty":-2.44059,"median":-0.746063,"eighty":-0.318638,"marketCap":17460908},{"date":"2022-08-26","current":2.616146,"twenty":-2.44059,"median":-0.746063,"eighty":-0.306736,"marketCap":18428131},{"date":"2022-09-02","current":2.579939,"twenty":-2.44059,"median":-0.746063,"eighty":-0.291531,"marketCap":18173090},{"date":"2022-09-09","current":2.764298,"twenty":-2.44059,"median":-0.745751,"eighty":-0.272385,"marketCap":19471713},{"date":"2022-09-16","current":2.587238,"twenty":-2.44059,"median":-0.745751,"eighty":-0.261309,"marketCap":18224505},{"date":"2022-09-23","current":2.2548,"twenty":-2.44059,"median":-0.745751,"eighty":-0.238037,"marketCap":15882809},{"date":"2022-09-30","current":2.196984,"twenty":-2.44059,"median":-0.744541,"eighty":2.2548,"marketCap":15475557},{"date":"2022-10-07","current":2.124715,"twenty":-2.44059,"median":-0.743341,"eighty":2.260582,"marketCap":14966493},{"date":"2022-10-14","current":2.045219,"twenty":-2.44059,"median":-0.739917,"eighty":2.260582,"marketCap":14406522},{"date":"2022-10-21","current":2.059673,"twenty":-2.44059,"median":-0.737228,"eighty":2.260582,"marketCap":14508335},{"date":"2022-10-28","current":2.16085,"twenty":-2.44059,"median":-0.733054,"eighty":2.260582,"marketCap":15221025},{"date":"2022-11-04","current":2.074127,"twenty":-2.44059,"median":-0.730668,"eighty":2.260582,"marketCap":14610148},{"date":"2022-11-11","current":2.507275,"twenty":-2.44059,"median":-0.728605,"eighty":2.298162,"marketCap":16039037},{"date":"2022-11-18","current":2.483396,"twenty":-2.44059,"median":-0.728605,"eighty":2.476795,"marketCap":15886284},{"date":"2022-11-25","current":2.316244,"twenty":-2.44059,"median":-0.728605,"eighty":2.476795,"marketCap":14817015},{"date":"2022-12-02","current":2.467556,"twenty":-2.44059,"median":-0.728605,"eighty":2.478834,"marketCap":15784958},{"date":"2022-12-09","current":2.764529,"twenty":-2.44059,"median":-0.728025,"eighty":2.519025,"marketCap":17684693},{"date":"2022-12-16","current":1.719274,"twenty":-2.44059,"median":-0.727014,"eighty":2.542431,"marketCap":10998197},{"date":"2022-12-23","current":1.647638,"twenty":-2.44059,"median":-0.722548,"eighty":2.542431,"marketCap":10539939},{"date":"2022-12-30","current":1.846628,"twenty":-2.44059,"median":-0.719816,"eighty":2.542431,"marketCap":11812878},{"date":"2023-01-06","current":1.735193,"twenty":-2.44059,"median":-0.719816,"eighty":2.483396,"marketCap":11100032},{"date":"2023-01-13","current":1.790911,"twenty":-2.44059,"median":-0.719816,"eighty":2.467509,"marketCap":11456455},{"date":"2023-01-20","current":1.910305,"twenty":-2.44059,"median":-0.719816,"eighty":2.407217,"marketCap":12220219},{"date":"2023-01-27","current":1.902345,"twenty":-2.44059,"median":-0.719816,"eighty":2.306693,"marketCap":12169301},{"date":"2023-02-03","current":1.703355,"twenty":-2.44059,"median":-0.719816,"eighty":2.257091,"marketCap":10896362},{"date":"2023-02-10","current":1.679476,"twenty":-2.44059,"median":-0.719816,"eighty":2.192648,"marketCap":10743609},{"date":"2023-02-17","current":1.587383,"twenty":-2.44059,"median":-0.719816,"eighty":2.166632,"marketCap":10154492},{"date":"2023-02-24","current":1.59988,"twenty":-2.44059,"median":-0.719816,"eighty":2.134833,"marketCap":10234433},{"date":"2023-03-03","current":1.711315,"twenty":-2.44059,"median":-0.719816,"eighty":2.103034,"marketCap":10947279},{"date":"2023-03-10","current":1.480486,"twenty":-2.44059,"median":-0.719816,"eighty":2.062564,"marketCap":9470669},{"date":"2023-03-17","current":1.40885,"twenty":-2.44059,"median":-0.719816,"eighty":2.025349,"marketCap":9012411},{"date":"2023-03-24","current":1.472526,"twenty":-2.44059,"median":-0.719816,"eighty":1.93461,"marketCap":9419752},{"date":"2023-03-31","current":1.639331,"twenty":-2.439915,"median":-0.71945,"eighty":1.902345,"marketCap":13158908},{"date":"2023-04-06","current":1.474189,"twenty":-2.439915,"median":-0.71945,"eighty":1.846628,"marketCap":11833318},{"date":"2023-04-14","current":1.704572,"twenty":-2.44059,"median":-0.719816,"eighty":1.817973,"marketCap":13682600},{"date":"2023-04-21","current":1.650459,"twenty":-2.44059,"median":-0.719816,"eighty":1.790911,"marketCap":13248231},{"date":"2023-04-28","current":1.777625,"twenty":-2.44059,"median":-0.719816,"eighty":1.741561,"marketCap":14268997},{"date":"2023-05-05","current":1.56027,"twenty":-2.44059,"median":-0.719816,"eighty":1.719274,"marketCap":12524284},{"date":"2023-05-12","current":1.524194,"twenty":-2.44059,"median":-0.719816,"eighty":1.711315,"marketCap":12234705},{"date":"2023-05-19","current":0.661443,"twenty":-2.44059,"median":-0.719816,"eighty":1.695553,"marketCap":12234705},{"date":"2023-05-26","current":0.642423,"twenty":-2.44059,"median":-0.719816,"eighty":1.682299,"marketCap":11882897},{"date":"2023-06-02","current":0.618775,"twenty":-2.44059,"median":-0.719816,"eighty":1.671516,"marketCap":11445489},{"date":"2023-06-09","current":0.63454,"twenty":-2.44059,"median":-0.719816,"eighty":1.655597,"marketCap":11737094},{"date":"2023-06-16","current":0.630599,"twenty":-2.44059,"median":-0.719816,"eighty":1.642208,"marketCap":11664193},{"date":"2023-06-23","current":0.563598,"twenty":-2.441264,"median":-0.720122,"eighty":1.63214,"marketCap":10424873},{"date":"2023-06-30","current":0.571481,"twenty":-2.441939,"median":-0.720428,"eighty":1.615799,"marketCap":10570675},{"date":"2023-07-07","current":0.591379,"twenty":-2.441939,"median":-0.720428,"eighty":1.599173,"marketCap":10938742},{"date":"2023-07-14","current":0.636199,"twenty":-2.441939,"median":-0.720428,"eighty":1.586653,"marketCap":11767766},{"date":"2023-07-21","current":0.428256,"twenty":-2.441939,"median":-0.720428,"eighty":1.558393,"marketCap":7921442},{"date":"2023-07-28","current":0.424177,"twenty":-2.441939,"median":-0.720428,"eighty":1.502919,"marketCap":7846000},{"date":"2023-08-04","current":0.244717,"twenty":-2.441939,"median":-0.720428,"eighty":1.479227,"marketCap":4526538},{"date":"2023-08-11","current":-0.252576,"twenty":-2.441939,"median":-0.720428,"eighty":1.43432,"marketCap":4410226},{"date":"2023-08-18","current":-0.276461,"twenty":-2.441939,"median":-0.720428,"eighty":0.723408,"marketCap":4827284},{"date":"2023-08-25","current":-0.254418,"twenty":-2.441939,"median":-0.720428,"eighty":0.661992,"marketCap":4442392},{"date":"2023-09-01","current":-0.290386,"twenty":-2.441939,"median":-0.720428,"eighty":0.646249,"marketCap":5070435},{"date":"2023-09-08","current":-0.263988,"twenty":-2.441939,"median":-0.720428,"eighty":0.635867,"marketCap":4609486},{"date":"2023-09-15","current":-0.257586,"twenty":-2.441939,"median":-0.720428,"eighty":0.630506,"marketCap":4497706},{"date":"2023-09-22","current":-0.22109,"twenty":-2.441939,"median":-0.720428,"eighty":0.622717,"marketCap":3860444},{"date":"2023-09-29","current":-0.20822,"twenty":-2.441939,"median":-0.720428,"eighty":0.609249,"marketCap":3635732},{"date":"2023-10-06","current":-0.20921,"twenty":-2.441939,"median":-0.720428,"eighty":0.582476,"marketCap":3653017},{"date":"2023-10-13","current":-0.250788,"twenty":-2.441939,"median":-0.720428,"eighty":0.560099,"marketCap":4379012},{"date":"2023-10-20","current":-0.227029,"twenty":-2.441939,"median":-0.720428,"eighty":0.442123,"marketCap":3964158},{"date":"2023-10-27","current":-0.213299,"twenty":-2.443287,"median":-0.721556,"eighty":0.424177,"marketCap":3724407},{"date":"2023-11-03","current":-0.177598,"twenty":-2.443287,"median":-0.721556,"eighty":0.331961,"marketCap":3101031},{"date":"2023-11-10","current":-0.153773,"twenty":-2.443287,"median":-0.721556,"eighty":0.245484,"marketCap":2685025},{"date":"2023-11-17","current":-0.129865,"twenty":-2.443287,"median":-0.71945,"eighty":-0.117527,"marketCap":2097316},{"date":"2023-11-24","current":-0.209929,"twenty":-2.443287,"median":-0.713851,"eighty":-0.117527,"marketCap":3390347},{"date":"2023-12-01","current":-0.203984,"twenty":-2.443287,"median":-0.709909,"eighty":-0.117527,"marketCap":3294336},{"date":"2023-12-08","current":-0.210201,"twenty":-2.44295,"median":-0.705221,"eighty":-0.117764,"marketCap":3394751},{"date":"2023-12-15","current":-0.191985,"twenty":-2.44295,"median":-0.698297,"eighty":-0.117764,"marketCap":3100551},{"date":"2023-12-22","current":-0.201802,"twenty":-2.44295,"median":-0.696557,"eighty":-0.117764,"marketCap":3259102},{"date":"2023-12-29","current":-0.206602,"twenty":-2.443287,"median":-0.696557,"eighty":-0.117527,"marketCap":3336616},{"date":"2024-01-05","current":-0.206134,"twenty":-2.443624,"median":-0.696557,"eighty":-0.117289,"marketCap":3329059},{"date":"2024-01-12","current":-0.185952,"twenty":-2.443624,"median":-0.693423,"eighty":-0.117289,"marketCap":3003124},{"date":"2024-01-19","current":-0.211307,"twenty":-2.443961,"median":-0.688725,"eighty":-0.117052,"marketCap":3412604},{"date":"2024-01-26","current":-0.214349,"twenty":-2.443624,"median":-0.687824,"eighty":-0.117289,"marketCap":3461738},{"date":"2024-02-02","current":-0.211583,"twenty":-2.443624,"median":-0.686966,"eighty":-0.117289,"marketCap":3417070},{"date":"2024-02-09","current":-0.203286,"twenty":-2.443624,"median":-0.683062,"eighty":-0.117289,"marketCap":3283068},{"date":"2024-02-16","current":-0.217115,"twenty":-2.443624,"median":-0.67923,"eighty":-0.117289,"marketCap":3506405},{"date":"2024-02-23","current":-0.192223,"twenty":-2.443624,"median":-0.678183,"eighty":-0.117289,"marketCap":3104397},{"date":"2024-03-01","current":-0.235093,"twenty":-2.443287,"median":-0.675863,"eighty":-0.117527,"marketCap":3796745},{"date":"2024-03-08","current":-0.202221,"twenty":-2.443287,"median":-0.67223,"eighty":-0.117527,"marketCap":3520869},{"date":"2024-03-15","current":-0.154423,"twenty":-2.443287,"median":-0.667339,"eighty":-0.117527,"marketCap":2688663},{"date":"2024-03-22","current":-0.137265,"twenty":-2.443287,"median":-0.664222,"eighty":-0.117527,"marketCap":2389923},{"date":"2024-03-28","current":-0.124396,"twenty":-2.443287,"median":-0.663546,"eighty":-0.117527,"marketCap":2165867},{"date":"2024-04-05","current":-0.1054,"twenty":-2.443624,"median":-0.659831,"eighty":-0.109812,"marketCap":1835119},{"date":"2024-04-12","current":-0.029353,"twenty":-2.443624,"median":-0.653239,"eighty":-0.047026,"marketCap":511059},{"date":"2024-04-19","current":-0.064574,"twenty":-2.443624,"median":-0.647364,"eighty":-0.041513,"marketCap":1124300},{"date":"2024-04-26","current":-0.062756,"twenty":-2.443287,"median":-0.646527,"eighty":-0.047466,"marketCap":1092647},{"date":"2024-05-03","current":-0.104286,"twenty":-2.443287,"median":-0.646527,"eighty":-0.047466,"marketCap":1815723},{"date":"2024-05-10","current":-0.055607,"twenty":-2.443287,"median":-0.644437,"eighty":-0.045105,"marketCap":1502390},{"date":"2024-05-17","current":-0.047352,"twenty":-2.443287,"median":-0.641613,"eighty":-0.040152,"marketCap":1279362},{"date":"2024-05-24","current":-0.043409,"twenty":-2.443287,"median":-0.639004,"eighty":-0.037787,"marketCap":1172828},{"date":"2024-05-31","current":-0.107614,"twenty":-2.443287,"median":-0.639004,"eighty":-0.037787,"marketCap":2907509},{"date":"2024-06-07","current":-0.119469,"twenty":-2.443287,"median":-0.635199,"eighty":-0.037787,"marketCap":3227800},{"date":"2024-06-14","current":-0.115935,"twenty":-2.443287,"median":-0.628407,"eighty":-0.037787,"marketCap":3132325},{"date":"2024-06-21","current":-0.080325,"twenty":-2.443624,"median":-0.624514,"eighty":-0.034975,"marketCap":2170227},{"date":"2024-06-28","current":-0.046217,"twenty":-2.443624,"median":-0.620317,"eighty":-0.034975,"marketCap":1248681},{"date":"2024-07-05","current":-0.101777,"twenty":-2.443624,"median":-0.616122,"eighty":-0.034975,"marketCap":2749823},{"date":"2024-07-12","current":-0.1091,"twenty":-2.443624,"median":-0.61378,"eighty":-0.034975,"marketCap":2947652},{"date":"2024-07-19","current":-0.153451,"twenty":-2.443624,"median":-0.60978,"eighty":-0.034975,"marketCap":4145931},{"date":"2024-07-26","current":-0.143304,"twenty":-2.443624,"median":-0.6023,"eighty":-0.034975,"marketCap":3871797},{"date":"2024-08-02","current":-0.145396,"twenty":-2.443624,"median":-0.597967,"eighty":-0.034975,"marketCap":3928319},{"date":"2024-08-09","current":-0.141082,"twenty":-2.443624,"median":-0.59008,"eighty":-0.034975,"marketCap":3520428},{"date":"2024-08-16","current":-0.15792,"twenty":-2.443624,"median":-0.585677,"eighty":-0.034975,"marketCap":3940581},{"date":"2024-08-23","current":-0.152182,"twenty":-2.443624,"median":-0.577168,"eighty":-0.034975,"marketCap":3797390},{"date":"2024-08-30","current":-0.13591,"twenty":-2.443624,"median":-0.575266,"eighty":-0.034975,"marketCap":3391368},{"date":"2024-09-06","current":-0.124547,"twenty":-2.443624,"median":-0.572309,"eighty":-0.034975,"marketCap":3107812},{"date":"2024-09-13","current":-0.133985,"twenty":-2.443624,"median":-0.56487,"eighty":-0.034975,"marketCap":3343324},{"date":"2024-09-20","current":-0.091626,"twenty":-2.443624,"median":-0.554636,"eighty":-0.034975,"marketCap":2286339},{"date":"2024-09-27","current":-0.096581,"twenty":-2.443624,"median":-0.551427,"eighty":-0.034975,"marketCap":2409998},{"date":"2024-10-04","current":-0.091087,"twenty":-2.443624,"median":-0.551427,"eighty":-0.034975,"marketCap":2272898},{"date":"2024-10-11","current":-0.078375,"twenty":-2.443624,"median":-0.551427,"eighty":-0.034975,"marketCap":1955687},{"date":"2024-10-18","current":-0.106924,"twenty":-2.443624,"median":-0.550303,"eighty":-0.034975,"marketCap":2668068},{"date":"2024-10-25","current":-0.132079,"twenty":-2.443624,"median":-0.537303,"eighty":-0.034975,"marketCap":3295770},{"date":"2024-11-01","current":-0.133587,"twenty":-2.443624,"median":-0.536692,"eighty":-0.034975,"marketCap":3333405},{"date":"2024-11-08","current":-0.215861,"twenty":-2.443624,"median":-0.507418,"eighty":-0.034975,"marketCap":5120441},{"date":"2024-11-15","current":-0.164666,"twenty":-2.443624,"median":-0.489951,"eighty":-0.034975,"marketCap":3906048},{"date":"2024-11-22","current":-0.240132,"twenty":-2.443624,"median":-0.476778,"eighty":-0.034975,"marketCap":5696166},{"date":"2024-11-29","current":-0.218593,"twenty":-2.443624,"median":-0.458628,"eighty":-0.034975,"marketCap":5185233},{"date":"2024-12-06","current":-0.204593,"twenty":-2.443624,"median":-0.419596,"eighty":-0.034975,"marketCap":4853162},{"date":"2024-12-13","current":-0.086267,"twenty":-2.443624,"median":-0.399792,"eighty":-0.034975,"marketCap":2046333},{"date":"2024-12-20","current":-0.093016,"twenty":-2.443624,"median":-0.385345,"eighty":-0.034975,"marketCap":2206437},{"date":"2024-12-27","current":-0.101453,"twenty":-2.443624,"median":-0.346215,"eighty":-0.034975,"marketCap":2406568},{"date":"2025-01-03","current":-0.096602,"twenty":-2.443624,"median":-0.334226,"eighty":-0.034975,"marketCap":2291493},{"date":"2025-01-10","current":-0.101031,"twenty":-2.443961,"median":-0.318538,"eighty":-0.032164,"marketCap":2396561},{"date":"2025-01-17","current":-0.094071,"twenty":-2.443961,"median":-0.30666,"eighty":-0.032164,"marketCap":2231453},{"date":"2025-01-24","current":-0.099555,"twenty":-2.443961,"median":-0.29642,"eighty":-0.032164,"marketCap":2361538},{"date":"2025-01-31","current":-0.092383,"twenty":-2.443961,"median":-0.282914,"eighty":-0.032164,"marketCap":2191427},{"date":"2025-02-07","current":-0.084368,"twenty":-2.443961,"median":-0.27524,"eighty":-0.032164,"marketCap":2001304},{"date":"2025-02-14","current":-0.201873,"twenty":-2.443961,"median":-0.270257,"eighty":-0.032164,"marketCap":4871206},{"date":"2025-02-21","current":-0.209731,"twenty":-2.443961,"median":-0.268477,"eighty":-0.032164,"marketCap":5060804},{"date":"2025-02-28","current":-0.230885,"twenty":-2.443961,"median":-0.263328,"eighty":-0.032164,"marketCap":5571259},{"date":"2025-03-07","current":-0.153521,"twenty":-2.444298,"median":-0.260028,"eighty":-0.029353,"marketCap":3704450},{"date":"2025-03-14","current":-0.145663,"twenty":-2.444298,"median":-0.255856,"eighty":-0.029353,"marketCap":3514852},{"date":"2025-03-21","current":-0.155334,"twenty":-2.444298,"median":-0.254418,"eighty":-0.029353,"marketCap":3748203},{"date":"2025-03-28","current":-0.067694,"twenty":-2.444298,"median":-0.248676,"eighty":-0.029353,"marketCap":1633458},{"date":"2025-04-04","current":-0.19903,"twenty":-2.444298,"median":-0.240132,"eighty":-0.029353,"marketCap":4802588},{"date":"2025-04-11","current":-0.134913,"twenty":-2.443961,"median":-0.229287,"eighty":-0.032164,"marketCap":3255446},{"date":"2025-04-17","current":-0.11513,"twenty":-2.443961,"median":-0.225717,"eighty":-0.032164,"marketCap":2778088},{"date":"2025-04-25","current":-0.155129,"twenty":-2.444298,"median":-0.221264,"eighty":-0.029353,"marketCap":3743260},{"date":"2025-05-02","current":-0.129886,"twenty":-2.444298,"median":-0.218498,"eighty":-0.029353,"marketCap":3134160},{"date":"2025-05-09","current":-0.088235,"twenty":-2.444298,"median":-0.217115,"eighty":-0.029353,"marketCap":2129100},{"date":"2025-05-16","current":-0.084537,"twenty":-2.444298,"median":-0.215594,"eighty":-0.029353,"marketCap":2003858},{"date":"2025-05-23","current":-0.079253,"twenty":-2.444298,"median":-0.214349,"eighty":-0.029353,"marketCap":1878617},{"date":"2025-05-30","current":-0.134196,"twenty":-2.444298,"median":-0.212966,"eighty":-0.029353,"marketCap":3180978},{"date":"2025-06-06","current":-0.13648,"twenty":-2.444298,"median":-0.211583,"eighty":-0.029353,"marketCap":3235123},{"date":"2025-06-13","current":-0.13648,"twenty":-2.444298,"median":-0.21094,"eighty":-0.029353,"marketCap":3235123},{"date":"2025-06-20","current":-0.679947,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":16117454},{"date":"2025-06-27","current":-0.504992,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":11970328},{"date":"2025-07-03","current":-0.475286,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":11266191},{"date":"2025-07-11","current":-0.470596,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":11155011},{"date":"2025-07-18","current":-0.465906,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":11043832},{"date":"2025-07-25","current":-0.501865,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":11896208},{"date":"2025-08-01","current":-0.4362,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":10339695},{"date":"2025-08-08","current":-0.334577,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":7930805},{"date":"2025-08-15","current":-0.279182,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":6707352},{"date":"2025-08-22","current":-0.283288,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":6805990},{"date":"2025-08-29","current":-0.232652,"twenty":-2.444972,"median":-0.210339,"eighty":0.025461,"marketCap":5589460},{"date":"2025-09-05","current":-0.223072,"twenty":-2.445647,"median":-0.210201,"eighty":0.080275,"marketCap":5359306},{"date":"2025-09-12","current":-0.205281,"twenty":-2.444972,"median":-0.209929,"eighty":0.025461,"marketCap":4931877},{"date":"2025-09-19","current":-0.270971,"twenty":-2.444972,"median":-0.209413,"eighty":0.025461,"marketCap":6510077},{"date":"2025-09-26","current":-0.218966,"twenty":-2.444972,"median":-0.209413,"eighty":0.025461,"marketCap":5260668},{"date":"2025-10-03","current":-0.198438,"twenty":-2.444972,"median":-0.208489,"eighty":0.025461,"marketCap":4767481},{"date":"2025-10-10","current":-0.240863,"twenty":-2.444972,"median":-0.208216,"eighty":0.025461,"marketCap":5786735},{"date":"2025-10-17","current":-0.205281,"twenty":-2.444972,"median":-0.208052,"eighty":0.025461,"marketCap":4931877},{"date":"2025-10-24","current":-0.209387,"twenty":-2.444972,"median":-0.20789,"eighty":0.025461,"marketCap":5030514},{"date":"2025-10-31","current":-0.191596,"twenty":-2.444972,"median":-0.207147,"eighty":0.025461,"marketCap":4603085},{"date":"2025-11-07","current":-0.201175,"twenty":-2.435195,"median":-0.206543,"eighty":0.025461,"marketCap":4833239},{"date":"2025-11-14","current":-0.922949,"twenty":-2.164085,"median":-0.206078,"eighty":0.025461,"marketCap":24433216},{"date":"2025-11-21","current":-0.687438,"twenty":-1.695666,"median":-0.206078,"eighty":0.025461,"marketCap":18198533},{"date":"2025-11-28","current":-0.878392,"twenty":-1.509716,"median":-0.206078,"eighty":0.025461,"marketCap":23253681},{"date":"2025-12-05","current":-0.884758,"twenty":-1.361961,"median":-0.206078,"eighty":0.025461,"marketCap":23422186},{"date":"2025-12-12","current":-0.738359,"twenty":-1.335827,"median":-0.206078,"eighty":0.025461,"marketCap":19546573},{"date":"2025-12-19","current":-0.661977,"twenty":-1.321756,"median":-0.206078,"eighty":0.025461,"marketCap":17524513},{"date":"2025-12-26","current":-0.592024,"twenty":-1.298972,"median":-0.206078,"eighty":0.025461,"marketCap":15672644},{"date":"2026-01-02","current":-0.333464,"twenty":-1.258097,"median":-0.206078,"eighty":0.025461,"marketCap":8827790},{"date":"2026-01-09","current":-0.325331,"twenty":-1.223267,"median":-0.206078,"eighty":0.025461,"marketCap":8612478},{"date":"2026-01-16","current":-0.340362,"twenty":-1.194783,"median":-0.206078,"eighty":0.025461,"marketCap":9010404},{"date":"2026-01-23","current":-0.336593,"twenty":-1.097033,"median":-0.206078,"eighty":0.025461,"marketCap":8910621},{"date":"2026-01-30","current":-0.278547,"twenty":-1.068418,"median":-0.206078,"eighty":0.025461,"marketCap":7373963},{"date":"2026-02-06","current":-0.226531,"twenty":-1.057576,"median":-0.206078,"eighty":0.025461,"marketCap":5996958},{"date":"2026-02-13","current":-0.248393,"twenty":-1.017385,"median":-0.206078,"eighty":0.025461,"marketCap":6575699},{"date":"2026-02-20","current":-0.263093,"twenty":-0.999441,"median":-0.206078,"eighty":0.025461,"marketCap":6964853},{"date":"2026-02-27","current":-0.277039,"twenty":-0.979505,"median":-0.206078,"eighty":0.025461,"marketCap":7334050},{"date":"2026-03-06","current":-0.243493,"twenty":-0.958695,"median":-0.206078,"eighty":0.025461,"marketCap":6445981},{"date":"2026-03-13","current":-0.172254,"twenty":-0.948485,"median":-0.205281,"eighty":0.025461,"marketCap":4560083},{"date":"2026-03-20","current":-0.169616,"twenty":-0.923304,"median":-0.205265,"eighty":0.025461,"marketCap":4490235},{"date":"2026-03-27","current":-0.169993,"twenty":-0.89925,"median":-0.203635,"eighty":0.025461,"marketCap":4500213},{"date":"2026-04-02","current":-0.189771,"twenty":-0.892658,"median":-0.202383,"eighty":0.025461,"marketCap":4927793},{"date":"2026-04-10","current":-0.198873,"twenty":-0.878392,"median":-0.201193,"eighty":0.025461,"marketCap":5164138},{"date":"2026-04-17","current":-0.255304,"twenty":-0.870398,"median":-0.201193,"eighty":0.025461,"marketCap":6629477},{"date":"2026-04-24","current":-0.22231,"twenty":-0.859525,"median":-0.201193,"eighty":0.025461,"marketCap":5772726},{"date":"2026-05-01","current":-0.220717,"twenty":-0.845729,"median":-0.201193,"eighty":0.025461,"marketCap":5731366},{"date":"2026-05-08","current":-0.221172,"twenty":-0.838641,"median":-0.201193,"eighty":0.025461,"marketCap":5743183},{"date":"2026-05-15","current":-0.215812,"twenty":-0.832999,"median":-0.201193,"eighty":0.025461,"marketCap":5666371},{"date":"2026-05-22","current":-0.226839,"twenty":-0.823134,"median":-0.201175,"eighty":0.025461,"marketCap":5955894},{"date":"2026-05-29","current":-0.225039,"twenty":-0.812448,"median":-0.201175,"eighty":0.080275,"marketCap":5908625},{"date":"2026-06-05","current":-0.22864,"twenty":-0.798096,"median":-0.201175,"eighty":0.025461,"marketCap":6003163},{"date":"2026-06-12","current":-0.218738,"twenty":-0.784214,"median":-0.201175,"eighty":0.025461,"marketCap":5743183},{"date":"2026-06-18","current":-0.216037,"twenty":-0.776033,"median":-0.201175,"eighty":0.025461,"marketCap":5672280},{"date":"2026-06-26","current":-0.217366,"twenty":-0.756181,"median":-0.201175,"eighty":0.080275,"marketCap":5707160},{"date":"2026-07-02","current":-0.211196,"twenty":-0.748539,"median":-0.201175,"eighty":0.080275,"marketCap":5545167},{"date":"2026-07-10","current":-0.186992,"twenty":-0.73537,"median":-0.201175,"eighty":0.080275,"marketCap":4909653},{"date":"2026-07-17","current":-0.213569,"twenty":-0.719263,"median":-0.20052,"eighty":0.080275,"marketCap":5607472},{"date":"2026-07-24","current":-0.207399,"twenty":-0.712845,"median":-0.20052,"eighty":0.080275,"marketCap":5445478},{"date":"2026-07-31","current":-0.196009,"twenty":-0.703835,"median":-0.199645,"eighty":0.135089,"marketCap":5146413},{"date":"2026-08-07","current":-0.193161,"twenty":-0.696557,"median":-0.198865,"eighty":0.135089,"marketCap":5071647},{"date":"2026-08-14","current":-0.161363,"twenty":-0.690666,"median":-0.198186,"eighty":0.135089,"marketCap":4236757},{"date":"2026-08-21","current":-0.130235,"twenty":-0.680622,"median":-0.19707,"eighty":0.135089,"marketCap":3439249}],"updateTime":1787491470047},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APVO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2646802488","title":"Aptevo Therapeutics Posts Investor Presentation on Multispecific Immunotherapies for Cancer, Led by Mipletamig in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2646802488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646802488?lang=en_us&edition=fundamental","pubTime":"2026-06-26 00:25","pubTimestamp":1782404750,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics posts investor presentation on multispecific immunotherapies for cancer, led by mipletamig in AMLAptevo highlighted mipletamig in frontline AML with venetoclax-azacitidine, citing ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260625:nNDLbXg532:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645504076","title":"Aptevo Therapeutics files Form 3 initial beneficial ownership statement for Niowave Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2645504076","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645504076?lang=en_us&edition=fundamental","pubTime":"2026-06-22 23:45","pubTimestamp":1782143129,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics disclosed NioWave filed a Form 3 showing 98,522 shares of common stock held directly as of May 25, 2026.NioWave reported 53,201 warrants exercisable May 25, 2026, expiring May 25, 2031, with an exercise price of USD 8.The filing identified NioWave as a 10% owner.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL16WpBd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639121086","title":"Aptevo Therapeutics files Form 3 for SVP, CSO Mary Jo Janatpour","url":"https://stock-news.laohu8.com/highlight/detail?id=2639121086","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639121086?lang=en_us&edition=fundamental","pubTime":"2026-05-29 08:03","pubTimestamp":1780013023,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics named Mary Jo Janatpour as SVP, CSO in an initial Form 3 insider filing dated May 20.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260529:nNDLxn5d9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698760","title":"Aptevo Therapeutics names Mary Janatpour senior vice president, chief scientific officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698760","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698760?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:08","pubTimestamp":1779970084,"startTime":"0","endTime":"0","summary":"Aptevo appointed Mary J. Janatpour as senior vice president, chief scientific officer to lead research, preclinical development, pipeline strategy.She brings over 25 years of oncology R&D leadership across biotech, pharma, spanning target discovery, translational science, immuno-oncology.Previously held leadership roles at Novartis Institutes for Biomedical Research, Schering-Plough Biopharma, Chiron, focused on oncology biologics targets.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1hbRRg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638507010","title":"Aptevo, Niowave form 50/50 radiopharmaceutical oncology collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2638507010","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638507010?lang=en_us&edition=fundamental","pubTime":"2026-05-27 20:08","pubTimestamp":1779883689,"startTime":"0","endTime":"0","summary":"Niowave made an at-the-market equity investment at closing, taking a 7.9% stake with potential to reach 19.99% via warrants and future buys.Initial program targets Nectin-4 using Aptevo multispecific antibody assets paired with Niowave radioisotope supply, including Actinium-225.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief on May 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDLbmxc06:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635759578","title":"Aptevo Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635759578","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635759578?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:21","pubTimestamp":1778707289,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryAptevo Therapeutics Inc APVO.OQ reported a quarterly adjusted loss of 1 cent per share for the quarter ended Ma","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753225","title":"Aptevo net loss widens to $6.7 million in Q1 FY26; operating cash outflow rises to $8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753225","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753225?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:23","pubTimestamp":1778703835,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics posted a net loss of USD 6.7 million for Q1 2026, while net cash used in operating activities widened to USD 8 million.Research and development spending rose to USD 3.92 million, driven by higher mipletamig and employee costs, while general and administrative expense was flat at USD 2.8 million.Cash and cash equivalents totaled USD 14.5 million at March 31, 2026; financing cash inflow was USD 871,000 on common stock issuance under Yorkville standby equity purchase agreements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2XK69T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635731949","title":"Aptevo Therapeutics reports Q1 cash and cash equivalents $14.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2635731949","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635731949?lang=en_us&edition=fundamental","pubTime":"2026-05-14 00:25","pubTimestamp":1778689554,"startTime":"0","endTime":"0","summary":"“Aptevo is entering a defining period as a company, supported by growing clinical momentum, a committed leadership team, and a pipeline with the po...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-reports-q1-cash-and-cash-equivalents-14-5m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-reports-q1-cash-and-cash-equivalents-14-5m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278492","title":"Aptevo says RAINIER trial on track for 2026 completion, Phase 2 dose selection","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278492","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635278492?lang=en_us&edition=fundamental","pubTime":"2026-05-13 20:09","pubTimestamp":1778674147,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics reported updated interim results from its ongoing RAINIER study of mipletamig in frontline acute myeloid leukemia, with trial completion and Phase 2 dose selection targeted by end-2026.Results have already been presented in the update, showing broad clinical activity with a high rate of remission in patients treated with mipletamig alongside standard therapy.Safety profile appeared differentiated versus similar immune-oncology approaches, with no cytokine release syndrome reported in frontline patients in the dataset.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL42Hvg7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634013498","title":"Aptevo Therapeutics Inc  expected to post a loss of $5.60 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634013498","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634013498?lang=en_us&edition=fundamental","pubTime":"2026-05-09 07:28","pubTimestamp":1778282884,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics Inc  expected to post a loss of $5.60 a share - Earnings Preview Aptevo Therapeutics Inc APVO.OQ APVO.O is expected to  show no change in quarterly revenue when it reports  results","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2W7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633138253","title":"Aptevo says mipletamig combo shows 81% remission in frontline AML trial cohort 5","url":"https://stock-news.laohu8.com/highlight/detail?id=2633138253","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633138253?lang=en_us&edition=fundamental","pubTime":"2026-05-06 20:09","pubTimestamp":1778069368,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics reported new interim results from RAINIER, its Phase 1b dose-optimization study of mipletamig with venetoclax, azacitidine in frontline acute myeloid leukemia, with Phase 2 dose selection targeted for 2026.Across 31 evaluable patients through Cohort 5, responses and overall clinical benefit continued to compare favorably with historical outcomes for venetoclax with azacitidine alone.Safety remained favorable in the expanding dataset, supporting continued dose escalation into final cohorts intended to complete dose selection package.Trial remained on track to finish dose optimization in 2026, positioning program for planned Phase 2 regulatory interaction.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260506:nNDL2RL68N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622899876","title":"Roth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622899876","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622899876?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:25","pubTimestamp":1774625114,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Jonathan Aschoff maintained a Buy rating on Aptevo Therapeutics today and set a price target of $21.00. According to TipRanks, Asc...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-sticks-to-its-buy-rating-for-aptevo-therapeutics-apvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-sticks-to-its-buy-rating-for-aptevo-therapeutics-apvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622949408","title":"Aptevo Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2622949408","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622949408?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:57","pubTimestamp":1774562269,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics Inc reports results for the quarter ended September 30 - Earnings SummaryAptevo Therapeutics Inc APVO.OQ reported a quarterly adjusted loss of $33.48 per share for the quarter ende","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL8N40E2LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622502938","title":"Aptevo Therapeutics Q4 EPS $(6.23) Beats $(8.10) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622502938","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622502938?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:55","pubTimestamp":1774529740,"startTime":"0","endTime":"0","summary":"Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(6.23) per share which beat the analyst consensus estimate of $(8.10) by 23.09 percent. This is a 97.38 percent increase over losses of $(237.60) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51480151/aptevo-therapeutics-q4-eps-6-23-beats-8-10-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622136857","title":"Aptevo Therapeutics reports FY25 EPS  ($87.27) vs. ($31,460.23) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2622136857","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622136857?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:20","pubTimestamp":1774527647,"startTime":"0","endTime":"0","summary":"“2025 was a year of meaningful progress across our clinical programs, pipeline strategy and capital position,” said Marvin White, CEO. “Most import...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-reports-fy25-eps-87-27-vs-31460-23-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-reports-fy25-eps-87-27-vs-31460-23-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622571328","title":"Aptevo Therapeutics sees cash runway into 4Q26","url":"https://stock-news.laohu8.com/highlight/detail?id=2622571328","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622571328?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:20","pubTimestamp":1774527619,"startTime":"0","endTime":"0","summary":"Aptevo ended 2025 with $21.6 million in cash and cash equivalents, compared with $8.7 million at December 31, 2024, and expects current resources t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-sees-cash-runway-into-4q26-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aptevo-therapeutics-sees-cash-runway-into-4q26-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["APVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622852089","title":"Aptevo Therapeutics FY2025 loss per share narrows to $87.27; cash and cash equivalents jump 148% to $22 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622852089","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622852089?lang=en_us&edition=fundamental","pubTime":"2026-03-26 20:06","pubTimestamp":1774526819,"startTime":"0","endTime":"0","summary":"Aptevo published a full-year earnings release reporting 2025 financial results and a business update.Net loss was USD 26.0 million and loss from operations was USD 26.3 million.Research and development expense was USD 14.5 million, up 1.13%, driven by higher mipletamig and employee costs and partly offset by lower ALG.APV-527 costs as the dose escalation trial concluded.General and administrative expense was USD 11.8 million, up 15.66%, mainly due to higher employee, consulting, and legal costs.Cash and cash equivalents ended 2025 at USD 21.6 million, and management said current resources are expected to fund operations into Q4 2026 while a USD 60.0 million equity line is expected, if fully utilized alongside current resources, to support operations into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL9WHLGl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621054777","title":"Aptevo highlights mipletamig AML data showing 79% remission rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2621054777","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621054777?lang=en_us&edition=fundamental","pubTime":"2026-03-23 20:40","pubTimestamp":1774269649,"startTime":"0","endTime":"0","summary":"Aptevo highlighted mipletamig as its lead clinical-stage asset, positioning it as a potential addition to frontline AML treatment alongside existing standard-of-care regimens.Reported frontline combination results showed 79% remission  and no CRS in frontline patients, which could support broader adoption if confirmed in further studies.The company also presented ALG.APV-527 as a partnered solid-tumor program, with early Phase 1 data showing 59% stable disease among 17 efficacy-evaluable patients.Aptevo said it is expanding beyond bispecifics into trispecific candidates, aiming to create additional partnering and pipeline value across multiple tumor types.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. publishe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL2WGvYL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247004","title":"Aptevo Therapeutics to present at Roth Conference and BIO-Europe Spring","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247004?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:06","pubTimestamp":1773922001,"startTime":"0","endTime":"0","summary":"Aptevo will attend the 38th Annual Roth Conference on March 22-24, 2026, in Dana Point, California.Jeff Lamothe is scheduled for a fireside chat on March 23, 2026, at 1:30 PM Pacific Time.BIO-Europe Spring is scheduled for March 23-25, 2026, in Lisbon, Portugal.Michelle H. Nelson is scheduled to present on March 24, 2026, at 1:15 PM Eastern Time .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6VXG0p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618943144","title":"Aptevo reports 86% clinical benefit rate and 0% CRS for mipletamig plus venetoclax and azacitidine in frontline AML trial data","url":"https://stock-news.laohu8.com/highlight/detail?id=2618943144","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618943144?lang=en_us&edition=fundamental","pubTime":"2026-03-11 18:01","pubTimestamp":1773223304,"startTime":"0","endTime":"0","summary":"Aptevo reports 86% clinical benefit rate and 0% CRS for mipletamig plus venetoclax and azacitidine in frontline AML trial data. Aptevo reported new interim data from two trials of mipletamig combined with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients who are elderly or unfit for intensive chemotherapy. In 28 evaluable frontline patients, the combination showed an 86% clinical benefit rate and 0% cytokine release syndrome. Aptevo said 79% achieved complete remission or complete remission with incomplete blood marker recovery, and 61% achieved complete remission. Among patients who achieved complete remission or complete remission with incomplete blood marker recovery, 55% reached measurable residual disease-negative blast reductions, and 35% of remissions occurred in patients with TP53 mutations. The company did not state that these results were previously presented or will be presented in the future.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDL9FLq6D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":41,"code":"91000000","status":"200"}]}}